Nightmares and Hallucinations with Aprepitant and Opium Powder: a Suspected Drug-drug Interaction

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2018 Nov 28

PMID 30479035

Citations 1

Authors

Gregoire Narjoux

Justine Clarenne

Brahim Azzouz

Pauline-Sarai Zeller

Florian Slimano

Olivier Bouche

Affiliations

Soon will be listed here.

Abstract

Polypharmacy of elderly oncology patients and fragmented medication management are well-known risk factors for drug-drug interactions (DDIs). These interactions can occur among antineoplastic, ongoing chronic treatment(s) and chemotherapy-associated treatments, like antiemetics. Clinically relevant interactions based on enzyme- or transporter-inhibition phenomena of active drugs can increase the frequency of their DDIs. We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations. We discuss this DDI's hypothetical pharmacological mechanisms and management.

Citing Articles

Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction.

Narjoux G, Clarenne J, Azzouz B, Zeller P, Slimano F, Bouche O Br J Clin Pharmacol. 2018; 85(2):454-456.

PMID: 30479035 PMC: 6339988. DOI: 10.1111/bcp.13810.

References

Aapro M, Walko C . Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010; 21(12):2316-2323. DOI: 10.1093/annonc/mdq149. View

Narjoux G, Clarenne J, Azzouz B, Zeller P, Slimano F, Bouche O . Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. Br J Clin Pharmacol. 2018; 85(2):454-456. PMC: 6339988. DOI: 10.1111/bcp.13810. View

Harding S, Sharman J, Faccenda E, Southan C, Pawson A, Ireland S . The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2017; 46(D1):D1091-D1106. PMC: 5753190. DOI: 10.1093/nar/gkx1121. View

Alexander S, Fabbro D, Kelly E, Marrion N, Peters J, Faccenda E . THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol. 2017; 174 Suppl 1:S272-S359. PMC: 5650666. DOI: 10.1111/bph.13877. View

Zhang L, Schaner M, Giacomini K . Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998; 286(1):354-61. View

Coffman B, Rios G, King C, Tephly T . Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997; 25(1):1-4. View

Patel P, Leeder J, Piquette-Miller M, Dupuis L . Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. 2017; 83(10):2148-2162. PMC: 5595939. DOI: 10.1111/bcp.13322. View

Shadle C, Lee Y, Majumdar A, Petty K, Gargano C, Bradstreet T . Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004; 44(3):215-23. DOI: 10.1177/0091270003262950. View

Sanchez R, Wang R, Newton D, Bakhtiar R, Lu P, Chiu S . Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004; 32(11):1287-92. DOI: 10.1124/dmd.104.000216. View

10.

Balyan R, Zhang X, Chidambaran V, Martin L, Mizuno T, Fukuda T . OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children. Pharmacogenomics. 2017; 18(7):621-629. PMC: 5591462. DOI: 10.2217/pgs-2017-0002. View

11.

Fujiwara Y, Toyoda M, Chayahara N, Kiyota N, Shimada T, Imamura Y . Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. PLoS One. 2014; 9(8):e104215. PMC: 4133207. DOI: 10.1371/journal.pone.0104215. View

12.

Tzvetkov M, Dos Santos Pereira J, Meineke I, Saadatmand A, Stingl J, Brockmoller J . Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol. 2013; 86(5):666-78. DOI: 10.1016/j.bcp.2013.06.019. View

13.

Stone A, Mackenzie P, Galetin A, Houston J, Miners J . Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos. 2003; 31(9):1086-9. DOI: 10.1124/dmd.31.9.1086. View

14.

Lees J, Chan A . Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011; 12(13):1249-57. DOI: 10.1016/S1470-2045(11)70040-7. View

15.

Smith H . Opioid metabolism. Mayo Clin Proc. 2009; 84(7):613-24. PMC: 2704133. DOI: 10.1016/S0025-6196(11)60750-7. View

16.

Venkatasubramanian R, Fukuda T, Niu J, Mizuno T, Chidambaran V, Vinks A . ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014; 15(10):1297-309. PMC: 4190075. DOI: 10.2217/pgs.14.99. View

17.

Horn J, Hansten P, Chan L . Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007; 41(4):674-80. DOI: 10.1345/aph.1H423. View

18.

House L, Ramirez J, Seminerio M, Mirkov S, Ratain M . In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica. 2015; 45(11):990-8. PMC: 4844176. DOI: 10.3109/00498254.2015.1038743. View

19.

Dushenkov A, Kalabalik J, Carbone A, Jungsuwadee P . Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. J Oncol Pharm Pract. 2016; 23(4):296-308. DOI: 10.1177/1078155216631408. View

20.

Abbas O, Shamseddin A, Temraz S, Haydar A . Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient. BMJ Case Rep. 2013; 2013. PMC: 3603752. DOI: 10.1136/bcr-2012-007995. View